2019冠状病毒病大流行期间心力衰竭管理的考量——台湾心脏病学会共识
Considerations When Managing Heart Failure during the COVID-19 Pandemic-Consensus from the Taiwan Society of Cardiology.
作者信息
Lin Kun-Chang, Wang Chun-Chieh, Huang Wei-Chun, Hwang Juey-Jen
机构信息
Department of Critical Care Medicine, Kaohsiung Veterans General Hospital, Kaohsiung.
Division of Cardiology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital and Chang Gung University, Taoyuan.
出版信息
Acta Cardiol Sin. 2021 Mar;37(2):125-129. doi: 10.6515/ACS.202103_37(2).20200916A.
Abstract
Coronavirus disease 2019 (COVID-19) has spread rapidly around the world since December 2019. Acute heart failure has accounted for 23-24% of the initial presentations in patients with COVID-19 infection. Furthermore, COVID-19 might increase metabolic demand and cause acute decompensation of pre-existing stable heart failure. These patients are thus more susceptible to the evolution of more serious clinical symptoms and a higher mortality rate. Given the lack of knowledge about this new disease, this review provides recommendations for the management of heart failure during the COVID-19 pandemic in Taiwan.
摘要
自2019年12月以来，2019冠状病毒病（COVID-19）已在全球迅速传播。急性心力衰竭在COVID-19感染患者的初始表现中占23%-24%。此外，COVID-19可能会增加代谢需求，并导致既往稳定的心力衰竭急性失代偿。因此，这些患者更容易出现更严重的临床症状，死亡率也更高。鉴于对这种新疾病缺乏了解，本综述为台湾地区COVID-19大流行期间心力衰竭的管理提供了建议。
相似文献
1
Considerations When Managing Heart Failure during the COVID-19 Pandemic-Consensus from the Taiwan Society of Cardiology.2019冠状病毒病大流行期间心力衰竭管理的考量——台湾心脏病学会共识
Acta Cardiol Sin. 2021 Mar;37(2):125-129. doi: 10.6515/ACS.202103_37(2).20200916A.
2
Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology.COVID-19 合并心力衰竭患者的管理：中国心力衰竭协会、国家心力衰竭委员会和欧洲心脏病学会心力衰竭协会联合立场文件。
Eur J Heart Fail. 2020 Jun;22(6):941-956. doi: 10.1002/ejhf.1915. Epub 2020 Jul 13.
3
Cardiovascular disease and COVID-19: Australian and New Zealand consensus statement.心血管疾病与 COVID-19：澳大利亚和新西兰共识声明。
Med J Aust. 2020 Aug;213(4):182-187. doi: 10.5694/mja2.50714. Epub 2020 Jul 31.
4
Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance.COVID-19 大流行期间血液科和肿瘤科患者的管理：临时共识指南。
Med J Aust. 2020 Jun;212(10):481-489. doi: 10.5694/mja2.50607. Epub 2020 May 13.
5
Management of acute myocardial infarction during the COVID-19 pandemic: A Consensus Statement from the Society for Cardiovascular Angiography and Interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP).COVID-19 大流行期间急性心肌梗死的管理：心血管血管造影和介入学会（SCAI）、美国心脏病学会（ACC）和美国急诊医师学会（ACEP）的共识声明。
Catheter Cardiovasc Interv. 2020 Aug;96(2):336-345. doi: 10.1002/ccd.28946. Epub 2020 May 13.
6
Coronavirus Disease-19 (COVID-19) and Heart Failure: Current Perspective.冠状病毒病-19（COVID-19）与心力衰竭：当前观点
J Assoc Physicians India. 2020 Nov;68(11):66-68.
7
Modeling and tracking Covid-19 cases using Big Data analytics on HPCC system platformm.在惠普高性能计算集群（HPCC）系统平台上使用大数据分析对新冠病毒疾病（Covid-19）病例进行建模和追踪。
J Big Data. 2021;8(1):33. doi: 10.1186/s40537-021-00423-z. Epub 2021 Feb 15.
8
The Coronavirus Pandemic: What Does the Evidence Show?新冠疫情：证据表明了什么？
J Nepal Health Res Counc. 2020 Apr 19;18(1):1-9. doi: 10.33314/jnhrc.v18i1.2596.
9
Heart Failure in the Time of COVID-19.新冠疫情期间的心力衰竭
Cardiology. 2020;145(8):481-484. doi: 10.1159/000509181. Epub 2020 Jun 26.
10
[Consensus Report from Turkish Society of Cardiology: COVID-19 and Cardiovascular Diseases. What cardiologists should know. (25th March 2020)].[土耳其心脏病学会共识报告：2019冠状病毒病与心血管疾病。心脏病专家应了解的内容。（2020年3月25日）]
Turk Kardiyol Dern Ars. 2020 Mar;48(Suppl 1):1-48. doi: 10.5543/tkda.2020.97198.
引用本文的文献
1
COVID-19 worsens quality of life in elderly heart failure patients: a clinical study.新冠病毒肺炎恶化老年心力衰竭患者的生活质量：一项临床研究。
Am J Transl Res. 2025 Feb 15;17(2):1416-1427. doi: 10.62347/ATQD2701. eCollection 2025.
2
Negative effects of COVID-19 on the implantation rate of cardiac resynchronization therapy with defibrillator device.新冠病毒病对植入式心脏复律除颤器心脏再同步治疗植入率的负面影响。
J Arrhythm. 2024 Jan 16;40(2):237-246. doi: 10.1002/joa3.12994. eCollection 2024 Apr.
3
β-adrenergic receptor signaling mediated by β-arrestins and its potential role in heart failure.由β-抑制蛋白介导的β-肾上腺素能受体信号传导及其在心力衰竭中的潜在作用。
Curr Opin Physiol. 2024 Feb;37. doi: 10.1016/j.cophys.2023.100723. Epub 2023 Nov 18.
4
COVID-19 Fear and Anxiety among Patients with Chronic Heart Failure: A Cross Sectional Study.慢性心力衰竭患者的新冠恐惧与焦虑：一项横断面研究
J Clin Med. 2022 Nov 7;11(21):6586. doi: 10.3390/jcm11216586.
5
Beta receptor blocker therapy for the elderly in the COVID-19 era.新冠疫情时代老年人的β受体阻滞剂治疗
World J Clin Cases. 2022 Aug 16;10(23):8088-8096. doi: 10.12998/wjcc.v10.i23.8088.
6
The impact of the COVID-19 pandemic on heart failure management: Global experience of the OPTIMIZE Heart Failure Care network.COVID-19 大流行对心力衰竭管理的影响：OPTIMIZE 心力衰竭护理网络的全球经验。
Int J Cardiol. 2022 Sep 15;363:240-246. doi: 10.1016/j.ijcard.2022.06.022. Epub 2022 Jun 22.
7
COVID-19 Screening for Hospitalized Patients: The Role of Expanded Hospital Surveillance in a Low Prevalence Setting.住院患者的新冠病毒病筛查：扩大医院监测在低流行环境中的作用
J Multidiscip Healthc. 2021 Oct 27;14:3027-3034. doi: 10.2147/JMDH.S337258. eCollection 2021.
本文引用的文献
1
COVID-19 Illness and Heart Failure: A Missing Link?新冠病毒疾病与心力衰竭：一个缺失的环节？
JACC Heart Fail. 2020 Jun;8(6):512-514. doi: 10.1016/j.jchf.2020.03.004. Epub 2020 Apr 10.
2
COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options.COVID-19 与心血管系统：对风险评估、诊断和治疗选择的影响。
Cardiovasc Res. 2020 Aug 1;116(10):1666-1687. doi: 10.1093/cvr/cvaa106.
3
Coronavirus Disease 2019 (COVID-19) Information for Cardiologists - Systematic Literature Review and Additional Analysis.新型冠状病毒病 2019（COVID-19）心内科医生相关信息 - 系统文献回顾和额外分析。
Circ J. 2020 May 25;84(6):1039-1043. doi: 10.1253/circj.CJ-20-0302. Epub 2020 Apr 29.
4
SARS-CoV-2 as potential cause of cardiac inflammation and heart failure. Is it the virus, hyperinflammation, or MODS?严重急性呼吸综合征冠状病毒2作为心脏炎症和心力衰竭的潜在病因。是病毒、过度炎症还是多器官功能障碍综合征？
Herz. 2020 Jun;45(4):321-322. doi: 10.1007/s00059-020-04925-z.
5
Cardiovascular complications in COVID-19.COVID-19 中的心血管并发症。
Am J Emerg Med. 2020 Jul;38(7):1504-1507. doi: 10.1016/j.ajem.2020.04.048. Epub 2020 Apr 18.
6
Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.住院 COVID-19 合并高血压患者中血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂的住院使用率与死亡率的关系。
Circ Res. 2020 Jun 5;126(12):1671-1681. doi: 10.1161/CIRCRESAHA.120.317134. Epub 2020 Apr 17.
7
Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2.新型冠状病毒肺炎疫情时期的心血管药理学：聚焦血管紧张素转换酶 2
J Cardiovasc Pharmacol. 2020 Jun;75(6):526-529. doi: 10.1097/FJC.0000000000000840.
8
Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB.COVID-19 感染患者服用 ACEI/ARB 的结果。
Curr Cardiol Rep. 2020 Apr 14;22(5):31. doi: 10.1007/s11886-020-01291-4.
9
Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19).心血管因素在治疗新型冠状病毒病 2019（COVID-19）患者中的考虑。
J Cardiovasc Pharmacol. 2020 May;75(5):359-367. doi: 10.1097/FJC.0000000000000836.
10
First case of COVID-19 complicated with fulminant myocarditis: a case report and insights.首例 COVID-19 合并暴发性心肌炎：病例报告及启示
Infection. 2020 Oct;48(5):773-777. doi: 10.1007/s15010-020-01424-5. Epub 2020 Apr 10.
Zotero 插件